PRLD News and Press, Prelude Therapeutics Incorporated From 06/02/21

WILMINGTON, Del., June 02, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences: 42 nd Annual Go...

Despite a ~7.5% gain yesterday, Prelude Therapeutics ([[PRLD]] -2.1%) has resumed its recent losing streak today.Earlier this week, it was reported that its largest institutional investor Orbimed Advisors has cut its ownership stake at the company to ~21.6% with the sale of 5.5...

Prelude Therapeutics (PRLD): Q1 GAAP EPS of -$0.47 misses by $0.05.Cash and cash equivalents of $362.99M.Press Release For further details see: Prelude Therapeutics EPS misses by $0.05

- Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 - - Initial Clinical Data Readouts for Lead Oral PRMT5 Inhibitors PRT543 and PRT811 Expected in 2H21 - - Dose Escalation Ongoing...

WILMINGTON, Del., May 05, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Off...

The anticipated impact on healthcare in a post-pandemic setup has led to contrasting views on two different healthcare providers: HCA Healthcare and LHC Group. Furthermore, several initiations are also included in today’s analyst action.HCA Healthcare downgraded at CitiCiti analysts Ra...

Gainers: Sypris Solutions (SYPR) +75%.Ocugen (OCGN) +41%.Brooklyn ImmunoTherapeutics (BTX) +34%.MicroVision (MVIS) +32%.BioVie (BIVI) +29%.FreightCar America (RAIL) +27%.Uxin (UXIN) +26%.Birks Group (BGI) +24%.Meridian Bancorp (EBSB) +21%.22nd Century (XXII) +20%.Losers: I...

The following slide deck was published by Prelude Therapeutics Incorporated in conjunction with this event. For further details see: Prelude Therapeutics (PRLD) Investor Presentation - Slideshow

Prelude Therapeutics (PRLD): Q4 GAAP EPS of -$0.45 beats by $0.13.Cash and cash equivalents of $218.3M as of December 31, 2020Press Release For further details see: Prelude Therapeutics EPS beats by $0.13

– Dose Escalation Portion of Phase 1 Trial of PRT543 Complete; Additional Expansion Cohorts Set to Initiate Early in the Second Quarter – – Clinical Data Readouts Expected in 2H21 for Lead PRMT5 Inhibitors PRT543 and PRT811 – – Phase 1 ...